Ivanhoe Mines achieved record production in Q3 2026 with 76,401 tonnes of saleable copper and 77,147 tonnes of zinc concentrate, solidifying its position among top global producers. The company ramped up its on-site hybrid solar facility to 60 MW, cutting diesel use by 40%, and plans to double solar capacity to 120 MW within 18 months. Construction on Platreef's Phase 2 concentrator is on schedule for completion by Q4 2027. Ivanhoe will release its Q3 financial results on November 3, 2026, followed by an investor call on November 4.
Ivanhoe Mines' Q3 2026 copper production is presented here alongside Pluang's market snapshot as of Oct 08, 2026 16:51 WIB: Among 150 US stocks priced on Pluang, 41 rose and 106 fell today. Applied Materials (AMAT) traded at USD 511.38 with a 1-day change of -1.78% and a typical hold time of 66 days, contrasting with Occidental Petroleum (OXY) at USD 59.23 gaining 1.75% but facing 98% sell activity and a longer hold time of 92 days. JetBlue Airways (JBLU) showed a price of USD 3.90, down 1.76%, with 69% sell orders and a shorter hold time of 44 days.
Futu Holdings Limited will announce its financial results for the third quarter ending September 30, 2026, on November 19 before U.S. market open. The company will host a live earnings conference call at 7:30 AM ET (8:30 PM Beijing/Hong Kong time) th...
Lorenz Snacks has introduced a fleet of four autonomous, electric vehicles from Einride at its production site in Neunburg vorm Wald, Germany. These vehicles will handle in-plant transport of goods and materials, replacing diesel trucks and significa...
UBS Group AG notified Bang & Olufsen A/S that its shareholding and voting rights exceeded 5% as of October 30, 2026, but fell below 5% by November 2, 2026. As of November 2, UBS held 4.66% of Bang & Olufsen's total shares and voting rights. This chan...
T-Therapeutics secured $133 million in an oversubscribed Series B funding round led by Advent Life Sciences and British Business Bank to develop its first-in-class TCR-CD3 bispecific therapies targeting cancer and autoimmune diseases. The funds will ...
Siemens Healthineers has begun separating its in vitro diagnostics business into a standalone company named Olyrian Diagnostics, expected to complete by mid-2028. This move aims to give the diagnostics unit a distinct market presence while continuing...
